Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI-534 in healthy infants and children
NCT00686075Phase 2Completed
- Sponsor
- MedImmune
- Start
- Jun 2008
- Primary completion
- Aug 2012
- Modality
- Live Attenuated Vaccines
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of MEDI-534 in respiratory syncytial virus infection (RSV) and Parainfluenza virus type 3 infection (HPIV-3) (10 arms), sponsored by MedImmune. Primary endpoints: Number of Participants With Solicited Symptoms, Number of Participants With Treatment-Emergent Adverse Events and 2 more. Started Jun 2008; status: completed.
02
Drugs
MEDI-534
03
Conditions
respiratory syncytial virus infection (RSV)Parainfluenza virus type 3 infection (HPIV-3)
Beyond the preview
Go deeper on NCT00686075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00686075.